In today’s session Supernus Pharmaceuticals Inc (SUPN) registered an unusually high (212) contracts volume of call trades. Someone, most probably a professional was a very active buyer of the November, 2016 call, expecting serious SUPN increase. With 212 contracts traded and 404 open interest for the Nov, 16 contract, it seems this is a quite bullish bet. The option with symbol: SUPN161118C00025000 closed last at: $1.15 or 23.3% down. About 193,667 shares traded hands. Supernus Pharmaceuticals Inc (NASDAQ:SUPN) has risen 40.14% since March 10, 2016 and is uptrending. It has outperformed by 32.62% the S&P500.
Analysts await Supernus Pharmaceuticals Inc (NASDAQ:SUPN) to report earnings on November, 1. They expect $0.21 earnings per share, up 162.50% or $0.13 from last year’s $0.08 per share. SUPN’s profit will be $9.74 million for 26.44 P/E if the $0.21 EPS becomes a reality. After $0.18 actual earnings per share reported by Supernus Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts 16.67% EPS growth.
Supernus Pharmaceuticals Inc (NASDAQ:SUPN) Ratings Coverage
Out of 3 analysts covering Supernus Pharmaceuticals (NASDAQ:SUPN), 1 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 33% are positive. Supernus Pharmaceuticals has been the topic of 6 analyst reports since August 26, 2015 according to StockzIntelligence Inc. The firm has “Hold” rating given on Wednesday, August 26 by Zacks. The rating was maintained by Northland Capital with “Outperform” on Thursday, November 5. The stock has “Neutral” rating given by Piper Jaffray on Monday, July 18. The firm has “Market Perform” rating by Northland Capital given on Monday, July 18. On Wednesday, October 28 the stock rating was initiated by Northland Capital with “Outperform”. Jefferies maintained it with “Buy” rating and $28 target price in Thursday, August 4 report.
According to Zacks Investment Research, “Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland.”
Insitutional Activity: The institutional sentiment increased to 1.26 in Q2 2016. Its up 0.11, from 1.15 in 2016Q1. The ratio is positive, as 27 funds sold all Supernus Pharmaceuticals Inc shares owned while 62 reduced positions. 25 funds bought stakes while 87 increased positions. They now own 45.62 million shares or 4.54% more from 43.64 million shares in 2016Q1.
Rhumbline Advisers has invested 0% of its portfolio in Supernus Pharmaceuticals Inc (NASDAQ:SUPN). Moreover, Great West Life Assurance Company Can has 0% invested in Supernus Pharmaceuticals Inc (NASDAQ:SUPN) for 5,200 shares. Diam Ltd holds 0.01% or 24,840 shares in its portfolio. Metropolitan Life Ny accumulated 0.01% or 34,803 shares. The Connecticut-based Aqr Ltd Co has invested 0.01% in Supernus Pharmaceuticals Inc (NASDAQ:SUPN). Architects last reported 106 shares in the company. Tiaa Cref Invest Mngmt Llc holds 0% of its portfolio in Supernus Pharmaceuticals Inc (NASDAQ:SUPN) for 251,350 shares. Cornerstone Mngmt Ltd Liability Com accumulated 0.02% or 97,900 shares. First Trust Advisors Limited Partnership holds 10,000 shares or 0% of its portfolio. D E Shaw Commerce, a New York-based fund reported 15,473 shares. Teachers Retirement Sys Of The State Of Kentucky has 0% invested in the company for 16,400 shares. Credit Suisse Ag last reported 90,151 shares in the company. Blackrock Japan accumulated 2,292 shares or 0% of the stock. 1492 Capital Limited Liability Com accumulated 19,530 shares or 0.36% of the stock. Ingalls And Snyder Lc holds 0.23% or 192,635 shares in its portfolio.
Insider Transactions: Since September 16, 2016, the stock had 0 buys, and 1 insider sale for $50,000 net activity. PATRICK GREGORY S sold 2,000 shares worth $50,000.
Supernus Pharmaceuticals, Inc. is a pharmaceutical firm focused on developing and commercializing products for the treatment of central nervous system diseases. The company has a market cap of $1.03 billion. The Firm offers products for the treatment of epilepsy, which include extended-release oxcarbazepine (Oxtellar XR) and extended-release topiramate (Trokendi XR). It has a 43.55 P/E ratio. It develops multiple product candidates in psychiatry for the treatment of Impulsive Aggression (IA) and attention deficit hyperactivity disorder (ADHD).
SUPN Company Profile
Supernus Pharmaceuticals, Inc. (Supernus), incorporated on March 30, 2005, is a pharmaceutical firm focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Firm offers products for the treatment of epilepsy, which include extended-release oxcarbazepine (Oxtellar XR) and extended-release topiramate (Trokendi XR). It is also engaged in developing multiple product candidates in psychiatry for the treatment of Impulsive Aggression (IA) and attention deficit hyperactivity disorder (ADHD). The Company’s psychiatry product candidates include SPN-810 (molindone hydrochloride) and SPN-812 (viloxazine hydrochloride). It is also developing SPN-810 as a treatment for IA in patients who have ADHD and SPN-812 for the treatment of ADHD. It is also developing SPN-809 (viloxazine hydrochloride) for the treatment of depression. The Firm markets its products in the United States through its own specialty sales force and has collaborations with other pharmaceutical companies to license its products outside the United States.
More news for Supernus Pharmaceuticals Inc (NASDAQ:SUPN) were recently published by: Investorplace.com, which released: “Supernus Pharmaceuticals Inc (SUPN) Stock Dips Despite Positive ADHD Data” on October 11, 2016. Seekingalpha.com‘s article titled: “Supernus: Reasonable Valuation And Strong Future Growth” and published on October 05, 2016 is yet another important article.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.